Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is in the spotlight today after announcing positive Phase 3 data for its cancer drug Ziihera® (zanidatamab‑hrii) in a large global trial for HER2‑positive gastroesophageal adenocarcinoma (GEA). The news has triggered sharp pre‑market moves in